Literature DB >> 11333868

Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree.

A Wagner1, Y Hendriks, E J Meijers-Heijboer, W J de Leeuw, H Morreau, R Hofstra, C Tops, E Bik, A H Bröcker-Vriends, C van Der Meer, D Lindhout, H F Vasen, M H Breuning, C J Cornelisse, C van Krimpen, M F Niermeijer, A H Zwinderman, J Wijnen, R Fodde.   

Abstract

Hereditary non-polyposis colorectal cancer (HNPCC) is the most common genetic susceptibility syndrome for colorectal cancer. HNPCC is most frequently caused by germline mutations in the DNA mismatch repair (MMR) genes MSH2 and MLH1. Recently, mutations in another MMR gene, MSH6 (also known as GTBP), have also been shown to result in HNPCC. Preliminary data indicate that the phenotype related to MSH6 mutations may differ from the classical HNPCC caused by defects in MSH2 and MLH1. Here, we describe an extended Dutch HNPCC family not fulfilling the Amsterdam criteria II and resulting from a MSH6 mutation. Overall, the penetrance of colorectal cancer appears to be significantly decreased (p<0.001) among the MSH6 mutation carriers in this family when compared with MSH2 and MLH1 carriers (32% by the age of 80 v >80%). Endometrial cancer is a frequent manifestation among female carriers (six out of 13 malignant tumours). Transitional cell carcinoma of the urinary tract is also relatively common in both male and female carriers (10% of the carriers). Moreover, the mean age of onset of both colorectal cancer (MSH6 v MSH2/MLH1 = 55 years v 44/41 years) and endometrial carcinomas (MSH6 v MSH2/MLH1 = 55 years v 49/48 years) is delayed. As previously reported, we confirm that the pattern of microsatellite instability, in combination with immunohistochemical analysis, can predict the presence of a MSH6 germline defect. The detailed characterisation of the clinical phenotype of this kindred contributes to the establishment of genotype-phenotype correlations in HNPCC owing to mutations in specific mismatch repair genes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11333868      PMCID: PMC1734864          DOI: 10.1136/jmg.38.5.318

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  46 in total

1.  Regulation of the human MSH6 gene by the Sp1 transcription factor and alteration of promoter activity and expression by polymorphisms.

Authors:  Isabella Gazzoli; Richard D Kolodner
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

Review 2.  History, genetics, and strategies for cancer prevention in Lynch syndrome.

Authors:  Fay Kastrinos; Elena M Stoffel
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

3.  Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures.

Authors:  Anja Wagner; Ingrid van Kessel; Mieke G Kriege; Carli M J Tops; Juul Th Wijnen; Hans F A Vasen; Conny A van der Meer; Iris I H van Oostrom; Hanne Meijers-Heijboer
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 4.  Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial Carcinoma.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2016-04-11

5.  MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer.

Authors:  Bente A Talseth-Palmer; Mary McPhillips; Claire Groombridge; Allan Spigelman; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2010-05-21       Impact factor: 2.857

Review 6.  Role of the clinical pathology laboratory in the evaluation of endometrial carcinomas for Lynch syndrome.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Semin Diagn Pathol       Date:  2014-04-02       Impact factor: 3.464

7.  Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers.

Authors:  Paul J Goodfellow; Barbara M Buttin; Thomas J Herzog; Janet S Rader; Randall K Gibb; Elizabeth Swisher; Katherine Look; Ken C Walls; Ming-Yu Fan; David G Mutch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

8.  MutSbeta exceeds MutSalpha in dinucleotide loop repair.

Authors:  J Kantelinen; M Kansikas; M K Korhonen; S Ollila; K Heinimann; R Kariola; M Nyström
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

9.  Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases.

Authors:  James Mueller; Isabella Gazzoli; Prathap Bandipalliam; Judy E Garber; Sapna Syngal; Richard D Kolodner
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

10.  MSH6 syndrome.

Authors:  Janina Suchy; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2008-06-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.